CN116323666A - Fgfr3抗体和使用方法 - Google Patents

Fgfr3抗体和使用方法 Download PDF

Info

Publication number
CN116323666A
CN116323666A CN202180051281.1A CN202180051281A CN116323666A CN 116323666 A CN116323666 A CN 116323666A CN 202180051281 A CN202180051281 A CN 202180051281A CN 116323666 A CN116323666 A CN 116323666A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
cdr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051281.1A
Other languages
English (en)
Chinese (zh)
Inventor
Y·萨巴格
陈扬德
W·布朗迪克
邱华伟
S·朴
R·魏
邱宇
周艳峰
C·勒穆瓦纳
H·曹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN116323666A publication Critical patent/CN116323666A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180051281.1A 2020-08-21 2021-08-20 Fgfr3抗体和使用方法 Pending CN116323666A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068575P 2020-08-21 2020-08-21
US63/068,575 2020-08-21
PCT/US2021/046958 WO2022040560A1 (en) 2020-08-21 2021-08-20 Fgfr3 antibodies and methods of use

Publications (1)

Publication Number Publication Date
CN116323666A true CN116323666A (zh) 2023-06-23

Family

ID=77774991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051281.1A Pending CN116323666A (zh) 2020-08-21 2021-08-20 Fgfr3抗体和使用方法

Country Status (14)

Country Link
US (2) US11505611B2 (cg-RX-API-DMAC10.html)
EP (1) EP4200019A1 (cg-RX-API-DMAC10.html)
JP (2) JP7858629B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230052963A (cg-RX-API-DMAC10.html)
CN (1) CN116323666A (cg-RX-API-DMAC10.html)
AR (1) AR123306A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021327387A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002455A2 (cg-RX-API-DMAC10.html)
CA (1) CA3189470A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023001559A2 (cg-RX-API-DMAC10.html)
IL (1) IL300623A (cg-RX-API-DMAC10.html)
MX (1) MX2023002106A (cg-RX-API-DMAC10.html)
TW (1) TW202229343A (cg-RX-API-DMAC10.html)
WO (1) WO2022040560A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
CN120456916A (zh) * 2022-11-14 2025-08-08 瑞泽恩制药公司 抗fgfr3抗体和抗原结合片段及其使用方法
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
WO2025207944A1 (en) * 2024-03-29 2025-10-02 Sidewinder Therapeutics, Inc. Fgfr3-iiib-binding antibodies
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247531A1 (en) * 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
CN105916523A (zh) * 2013-12-18 2016-08-31 英克隆有限责任公司 针对成纤维细胞生长因子受体-3(fgfr3)的化合物和治疗方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
DK0646182T3 (da) 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
AU6446194A (en) 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
EP1208231B2 (en) 1999-05-05 2009-12-30 Institut Curie Means for detecting and treating pathologies linked to fgfr3
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
AU7764200A (en) 1999-10-06 2001-05-10 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cellpopulations, and selecting cell populations for autologous transplantation
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
ES2363765T3 (es) 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistas de fgfr.
NZ537208A (en) 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
AU2003265057A1 (en) 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
CA2510715A1 (en) 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
US8124331B2 (en) 2003-03-26 2012-02-28 Progenika Biopharma, S.A. In vitro method to detect bladder transitional cell carcinoma
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1544213B1 (en) 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
AU2005216547B2 (en) 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
AU2005302083A1 (en) 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009511613A (ja) 2005-10-17 2009-03-19 エンカム ファーマシューティカルズ アクティーゼルスカブ 神経細胞接着分子l1のペプチド断片を含む新規fgf受容体結合化合物
WO2007067968A2 (en) 2005-12-08 2007-06-14 Novartis Ag Effects of inhibitors of fgfr3 on gene transcription
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
WO2008127707A1 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
WO2009146033A2 (en) 2008-03-31 2009-12-03 Sma Foundation Compositions and methods for modulating smn activity
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
KR20220017512A (ko) 2012-03-08 2022-02-11 아스테라스 세이야쿠 가부시키가이샤 신규 fgfr3 융합체
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20150292030A1 (en) 2012-11-27 2015-10-15 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
CN105209607B (zh) 2013-04-05 2020-02-07 大学健康网络 产生软骨细胞谱系细胞和/或类软骨组织的方法和组合物
SG11201706727XA (en) 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
CN110785184A (zh) 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法,组合物和试剂盒

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247531A1 (en) * 2009-03-25 2010-09-30 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
CN105916523A (zh) * 2013-12-18 2016-08-31 英克隆有限责任公司 针对成纤维细胞生长因子受体-3(fgfr3)的化合物和治疗方法

Also Published As

Publication number Publication date
JP2026126325A (ja) 2026-08-04
US20220056142A1 (en) 2022-02-24
JP7858629B2 (ja) 2026-05-14
EP4200019A1 (en) 2023-06-28
BR112023002455A2 (pt) 2023-03-28
IL300623A (en) 2023-04-01
WO2022040560A1 (en) 2022-02-24
AU2021327387A1 (en) 2023-05-04
AU2021327387A9 (en) 2023-07-06
TW202229343A (zh) 2022-08-01
JP2023538098A (ja) 2023-09-06
KR20230052963A (ko) 2023-04-20
MX2023002106A (es) 2023-03-15
AR123306A1 (es) 2022-11-16
CA3189470A1 (en) 2022-02-24
CO2023001559A2 (es) 2023-02-16
US20230303704A1 (en) 2023-09-28
US11505611B2 (en) 2022-11-22

Similar Documents

Publication Publication Date Title
JP7854419B2 (ja) 最適化された抗tl1a抗体
JP7610302B2 (ja) Ccr8抗体及びその用途
CA2932966C (en) Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof
JP7858629B2 (ja) Fgfr3抗体および使用の方法
JP2022507679A (ja) Her2/pd1二重特異性抗体
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
CN108948194B (zh) 一种新的ctla-4单克隆抗体
JP2024512351A (ja) Gdf-15に対する抗体
US20240228649A9 (en) Crtam antibodies and methods of treating cancer
JP2021515542A (ja) Pd1結合剤
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
JP7014783B2 (ja) 抗cd27抗体、その抗原結合性フラグメント、およびそのものの医学的使用
US20250277038A1 (en) Anti-pd-l1 antibody and use thereof
TW202221038A (zh) 抗trop-2抗體、其抗原結合片段或其突變體、及其醫藥用途
WO2025232811A1 (zh) 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40012331B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
HK40042163A (en) Optimized anti-tl1a antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination